Type 2
corticotropin-releasing factor receptor (CRFR2) is expressed in skeletal muscle and stimulation of the receptor has been shown to inhibit the effect of
insulin on
glucose uptake in muscle cells. Currently, little is known about the mechanisms underlying this process. In this study, we first showed that both in vivo and in vitro CRFR2 expression in muscle was closely correlated with
insulin sensitivity, with elevated receptor levels observed in
insulin resistant muscle cells. Stimulation of CRFR2 by
urocortin 2 (Ucn 2), a CRFR2-selective
ligand, in C2C12 myotubes greatly attenuated
insulin-induced
glucose uptake. The inhibitory effect of CRFR2 signaling required cAMP production and is involved the mammalian target of rapamycine pathway, as
rapamycin reversed the inhibitory effect of CRFR2 stimulation on
insulin-induced
glucose uptake. Moreover, stimulation of CRFR2 failed to inhibit
glucose uptake in muscle cells induced by
platelet-derived growth factor, which, similar to
insulin, signals through Akt-mediated pathway but is independently of
insulin receptor substrate (IRS)
proteins to promote
glucose uptake. This result argues that CRFR2 signaling modulates
insulin's action likely at the levels of IRS. Consistent with this notion, Ucn 2 reduced
insulin-induced
tyrosine phosphorylation of IRS-1, and treatment with
rapamycin reversed the inhibitory effect of Ucn 2 on IRS-1 and Akt phosphorylation. In conclusion, the inhibitory effect of CRFR2 signaling on
insulin action is mediated by cAMP in a mammalian target of rapamycine-dependent manner, and IRS-1 is a key nodal point where CRFR2 signaling modulates
insulin-stimulated
glucose uptake in muscle cells.